Mike Di Spirito

Mike is the Director, Clinical Pharmacology & Pharmacometrics, at Celerion and leads a team of 30 scientists developing study designs and trial protocols in early clinical research, creating statistical analysis plans, conducting pharmacokinetic and pharmacodynamic analyses, interpreting and discussing study results, and generating clinical study reports. He advises various biotech and pharmaceutical companies on a wide range of clinical pharmacology topics.  Over the last 20 years at Celerion and its legacy companies, Mike has worked on hundreds of NDA-enabling studies: First in Human single- and multiple-ascending dose, Radiolabeled ADME mass balance, Drug-drug interactions, Hepatic and Renal insufficiency, TQT, Microdosing, Microtracer, Bioavailability, Bioequivalence, Food-effect, and First in Patient signal effects.

Nathan Boublil

Nathan Boublil is co-founder and CEO of ZEN Rooms, now one of the leading hospitality companies in Southeast Asia (SEA). ZEN is dedicated to changing the state of budget hospitality in SEA through radical technological and operational improvements. ZEN grew to become within 4 years the largest and best-rated budget hotel franchise in the fast-growing Philippines and top 3 in SEA. With a team of 500 staff, ZEN is backed by Korean travel unicorn Yanolja and leading emerging market investors. Before becoming an entrepreneur, Nathan was previously Economic Advisor to the French Ministry of Foreign Affairs and an Investment Banker at Deutsche Bank in London. Economist by training, he graduated from the University of Cambridge where he was also a Research fellow. An avid traveler, he is fluent in 5 languages

Alyce King

Alyce King is a business development professional with 15+ years of experience in health care. She has been with Novotech for seven years working both in Australia and the United States. She holds a Bachelor of Science in Chemistry and Physiology from Monash University in Melbourne, Australia.